By Jasmine Li
Astellas Pharma's drug Vyloy was approved for treatment of advanced gastric and gastroesophageal junction cancer by the Food and Drug Administration.
The pharmaceutical company said Friday the FDA approved the drug for use in combination with fluoropyrimidine-and-platinum-containing chemotherapy. Vyloy is intended for the first-line treatment of patients whose tumors are claudin $(CLDN.UK)$ 18.2 positive, Astellas said.
The approval was based on results from Phase 3 clinical trials, and makes Vyloy the first and only CLDN18.2-targeted therapy approved in the U.S., the company said.
An FDA-approved test developed by Roche Holdings is used to identify patients who may be eligible for Vyloy, Astellas said. Vyloy was also approved in Japan, the U.K., the E.U. and South Korea this year.
Write to Jasmine Li at jasmine.li@wsj.com
(MORE TO FOLLOW) Dow Jones Newswires
October 18, 2024 15:29 ET (19:29 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。